Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities

Published:2017-07-12 Issue:4 Volume:13 Page:277-288
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Roberts Kate¹^ORCID,Culleton Vanessa¹,Lwin Zarnie¹²³,O'Byrne Kenneth⁴⁵,Hughes Brett GM¹²³

Affiliation:

1. Cancer Care Services; The Prince Charles Hospital; Brisbane Queensland Australia

2. Royal Brisbane and Women's Hospital; Herston Queensland Australia

3. School of Medicine; University of Queensland; Brisbane Queensland Australia

4. Princess Alexandra Hospital; Brisbane Queensland Australia

5. Queensland University of Technology; Brisbane Queensland Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12698/fullpdf

Reference66 articles.

1. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways;Fife;Immunol Rev,2008

2. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy;Peggs;Immunol Rev,2008

3. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

4. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

5. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer;Cancer Drug Resistance;2024-06-11

2. Development of Vogt–Koyanagi–Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report;BMC Ophthalmology;2024-06-07

3. Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review;Clinical and Translational Oncology;2024-04-24

4. Case report: A rare case of immunotherapy induced isolated left CN VI palsy in a patient with unresectable melanoma;Frontiers in Oncology;2024-02-12

5. Pembrolizumab (Keytruda®)-assoziierte Hypotonia bulbi;Die Ophthalmologie;2023-02-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3